AbbVie operates a broad, noncyclical pharmaceutical business spanning immunology, oncology, neuroscience and virology, with flagship products addressing chronic and life-threatening conditions. In the past five years, AbbVie’s annual revenue has ranged from $32 billion to $56 billion, and despite overall market volatility, its sell-through for key therapies has shown less than 5% variance in recessionary periods. This stability makes AbbVie a go-to defensive holding for investors seeking to balance exposure against the cyclical swings of technology names.

Analysts forecast AbbVie’s immunology portfolio—led by Skyrizi and Rinvoq—to deliver fourth-quarter sales of approximately $6 billion, representing a 15% year-over-year increase. These newer agents are expected to offset the revenue decline following the loss of Humira exclusivity in Europe and Japan. Institutional surveys show that demand for Skyrizi in plaque psoriasis has expanded at a 30% annualized rate through Q3, while Rinvoq prescriptions for rheumatoid arthritis climbed 22% sequentially in the U.S.

Since Humira patent expirations began in 2023, AbbVie has relied on an aggressive R&D and commercial deployment strategy to limit earnings erosion. The company has launched five new molecular entities worldwide in the past two years and maintains a late-stage pipeline of 12 candidates targeting oncology and immuno-inflammation. During the first nine months of fiscal 2025, AbbVie reported a 7% compound annual growth rate in operating income, underscoring its ability to navigate competitive pressures and patent expirations.

AbbVie has increased its dividend for 54 consecutive years, a hallmark of its commitment to shareholder returns. The current annual payout represents roughly 45% of trailing-twelve-month free cash flow, a ratio well below the 60% threshold that rating agencies view as sustainable. Since splitting from its parent company in 2013, AbbVie’s total dividend distribution has grown by an average of 10% per year, demonstrating its capacity to generate consistent cash flow even as it invests in pipeline expansion.